Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia

Iléana Antony‐Debré(Inserm), Hana Raslová(Inserm)

Blood

December 10, 2014

10.1182/blood-2014-06-585513

Cited by 96

Related Papers

MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations

|Blood|2012|79

The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

|Cancer Discovery|2020|26

The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

|Blood|2019|5

Data from The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

|Unknown|2023|0

Figure S10 from The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

|Unknown|2023|0